公开(公告)号：EP2625162B1

公开(公告)日：2019-03-13

申请号：EP11831546.4

申请日：2011-10-05

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith, H. ,  BEHLING, Jim ,  DOUGAN, Christine, Henderson ,  WATT, Stephen, William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： C07C51/41 ,  C07C227/18 ,  C07C229/26 ,  C07C57/46 ,  A61K31/198 ,  A61K31/192 ,  A61P1/16

公开(公告)号：EP3263100A1

公开(公告)日：2018-01-03

申请号：EP17185173.6

申请日：2010-04-01

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine Henderson ,  WATT, Stephen William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： A61K31/198 ,  A61P1/16 ,  C07C229/26 ,  A61K31/192 ,  C07C57/46 ,  C07C57/32

摘要： Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

公开(公告)号：EP2625162A1

公开(公告)日：2013-08-14

申请号：EP11831546.4

申请日：2011-10-05

申请人： Ocera Therapeutics Inc.

发明人： ANDERSON, Keith, H. ,  BEHLING, Jim ,  DOUGAN, Christine, Henderson ,  WATT, Stephen, William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： C07C227/18 ,  C07C229/26 ,  C07C57/46 ,  A61K31/198 ,  A61K31/192 ,  A61P1/16

CPC分类号： C07C227/18 ,  A61K31/192 ,  A61K31/198 ,  C07C51/412 ,  C07C229/26 ,  C07C57/32

摘要： Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

公开(公告)号：EP3263100B1

公开(公告)日：2020-04-01

申请号：EP17185173.6

申请日：2010-04-01

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine Henderson ,  WATT, Stephen William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： A61K31/198 ,  A61P1/16 ,  C07C229/26 ,  A61K31/192 ,  C07C57/46 ,  C07C57/32

公开(公告)号：EP2413924A1

公开(公告)日：2012-02-08

申请号：EP10759442.6

申请日：2010-04-01

申请人： Ocera Therapeutics, INC.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine, Henderson ,  WATT, Stephen, William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： A61K31/198 ,  A61P1/16 ,  C07C229/26 ,  A61K31/192 ,  C07C57/46

CPC分类号： C07C227/40 ,  A61K31/192 ,  A61K31/198 ,  A61K31/205 ,  C07C51/42 ,  C07C57/32 ,  C07C227/42 ,  C07C229/26

摘要： Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

公开(公告)号：EP4101838A1

公开(公告)日：2022-12-14

申请号：EP22185562.0

申请日：2010-04-01

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine Henderson ,  WATT, Stephen William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： C07C227/18 ,  C07C227/42 ,  C07C229/26 ,  C07C51/41 ,  C07C51/43 ,  C07C57/32

摘要： A process for making L-ornithine phenylacetate, comprising:
forming a solution of L-ornithine, wherein the solution comprises water;
adding a pH modifier to the solution;
adding phenylacetic acid to the solution ; and
isolating L-ornithine phenylacetate from the solution.

公开(公告)号：EP3686183A1

公开(公告)日：2020-07-29

申请号：EP20161306.4

申请日：2010-04-01

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine Henderson ,  WATT, Stephen William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： C07C229/26 ,  A61K31/198 ,  A61P1/16 ,  A61K31/192 ,  C07C57/46 ,  C07C57/32

摘要： Disclosed herein are crystalline forms of L-omithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

公开(公告)号：EP2413924B1

公开(公告)日：2017-09-27

申请号：EP10759442.6

申请日：2010-04-01

申请人： Ocera Therapeutics, Inc.

发明人： ANDERSON, Keith ,  BEHLING, Jim ,  DOUGAN, Christine, Henderson ,  WATT, Stephen, William ,  MANINI, Peter ,  FIGINI, Attilia

IPC分类号： A61K31/198 ,  A61P1/16 ,  C07C229/26 ,  A61K31/192 ,  C07C57/46 ,  C07C57/32

CPC分类号： C07C227/40 ,  A61K31/192 ,  A61K31/198 ,  A61K31/205 ,  C07C51/42 ,  C07C57/32 ,  C07C227/42 ,  C07C229/26